TABLE 5.
BAL eosinophilia in α-GalCer-treated vvGs- or FI-RSV-immunized mice following RSV challengea
| Priming group | No. of eosinophils (104) inb:
|
||
|---|---|---|---|
| CD1d+/+ mice
|
CD1d−/− mice | ||
| Vehicle | α-GalCer | Vehicle | |
| vac-lac | 1.49 ± 0.32 | Not tested | 0.75 ± 0.13 |
| vvGs | 12.63 ± 3.11 | 10.70 ± 2.76 | 17.41 ± 2.96 |
| FI-RSV | 11.86 ± 2.53 | 8.29 ± 1.43 (0.015) | 16.45 ± 2.13 |
a
Mice were immunized with vac-lac, vvGs, or FI-RSV and treated with α-GalCer or polysorbate vehicle. Six weeks later the mice were challenged with live RSV, and 7 days later BAL was performed. BAL cells were differentially stained and counted, and the numbers of eosinophils were calculated.
b
Data are presented as means ± SEMs. Numbers in parentheses are statistically significant P values (relative to vehicle-treated CD1d+/+ mice).